Fusion Antibodies plc (AIM:FAB)
London flag London · Delayed Price · Currency is GBP · Price in GBX
15.50
0.00 (0.00%)
Feb 12, 2026, 4:24 PM GMT

Fusion Antibodies Income Statement

Millions GBP. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
1.61.971.142.94.84.17
Revenue Growth (YoY)
-11.43%72.97%-60.84%-39.55%15.22%6.93%
Cost of Revenue
1.241.541.182.332.332.14
Gross Profit
0.350.43-0.050.572.472.02
Selling, General & Admin
1.922.0523.133.032.74
Research & Development
0.18-----
Other Operating Expenses
-0.37--0.01-0.01-0.03-0.19
Operating Expenses
1.822.162.233.473.793.27
Operating Income
-1.47-1.73-2.27-2.89-1.33-1.25
Interest Expense
-0.01-0-0.01-0-0.01-0.02
Interest & Investment Income
00.010000
Currency Exchange Gain (Loss)
-0.05-0.05-0.020.04--
EBT Excluding Unusual Items
-1.53-1.78-2.29-2.86-1.33-1.26
Pretax Income
-1.53-1.78-2.29-2.86-1.33-1.26
Income Tax Expense
-0.07-0.06-0.06-0.26-0.131.64
Net Income
-1.47-1.71-2.23-2.6-1.2-2.9
Net Income to Common
-1.47-1.71-2.23-2.6-1.2-2.9
Shares Outstanding (Basic)
1059656262625
Shares Outstanding (Diluted)
1059656262625
Shares Change (YoY)
31.30%72.58%113.55%0.27%1.91%15.24%
EPS (Basic)
-0.01-0.02-0.04-0.10-0.05-0.11
EPS (Diluted)
-0.01-0.02-0.04-0.10-0.05-0.11
Free Cash Flow
-1.25-1.37-1.77-1.87-0.59-1.5
Free Cash Flow Per Share
-0.01-0.01-0.03-0.07-0.02-0.06
Gross Margin
22.05%21.88%-3.96%19.79%51.39%48.59%
Operating Margin
-92.23%-87.84%-200.00%-99.76%-27.61%-29.99%
Profit Margin
-91.92%-87.18%-195.95%-89.49%-25.00%-69.60%
Free Cash Flow Margin
-78.26%-69.92%-155.90%-64.39%-12.25%-36.04%
EBITDA
-1.4-1.62-2.05-2.55-0.65-0.61
EBITDA Margin
-87.59%-82.65%-180.81%-87.80%-13.48%-14.60%
D&A For EBITDA
0.070.10.220.350.680.64
EBIT
-1.47-1.73-2.27-2.89-1.33-1.25
EBIT Margin
-92.23%-87.84%-200.00%-99.76%-27.61%-29.99%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.